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Abstract 
 
Background 
Tuberculosis, often undiagnosed, is the major cause of death among HIV-positive people. We tested 
an algorithm enabling nurses in South African primary healthcare clinics (PHCs) to initiate empirical 
tuberculosis treatment among adults with advanced HIV disease. 
Methods  
In an open-label cluster-randomised trial, 24 PHCs were randomised 1:1 to intervention or control 
(routine care) using computer-generated random numbers. HIV-positive adults were eligible if they 
had CD4 count ≤150 cells per µL; no antiretroviral therapy (ART) or tuberculosis treatment in the last 
six or three months respectively; and did not require urgent hospital referral. In intervention clinics, 
study nurses assessed participants based on tuberculosis symptoms, body mass index (BMI), point-
of-care haemoglobin, and urine lipoarabinomannan assay (Determine TB-LAM, Alere). A study 
algorithm assigned tuberculosis probability as high (positive urine TB-LAM or BMI <18·5 kg/m2 or 
haemoglobin <100 g/L), to start tuberculosis treatment immediately then ART two weeks later; 
medium (tuberculosis symptoms, no high probability criteria), to have symptom-guided 
investigation; or low (no tuberculosis symptoms or high probability criteria), to start ART 
immediately. The primary outcome was all-cause mortality at six months. (ISRCTN35344604) 
Findings 
3091 individuals were screened; 3053 assigned a study identifier; and 3022 (1507 intervention, 1515 
control; median age 37 years, 55·2% female, median CD4 72 cells per µL) analysed. 930/1507 
(61·7%) versus 172/1515 (11·4%) of participants in the intervention versus control arm started 
tuberculosis treatment by two months. The mortality rate was 19·0 (134 deaths/704 person-years 
[pyrs]) versus 21·6 (151/699 pyrs) per 100 pyrs in the intervention versus control arm (unadjusted 
hazard ratio [HR] 0·92, 95% CI 0·67–1·26; adjusted HR 0·87, 95% CI 0·61–1·24, p=0·41).  There were 
29 versus 11 serious or severe adverse events in the intervention versus control arm. 
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Interpretation 
Our intervention substantially increased coverage of tuberculosis treatment in this high-risk 
population, but did not reduce mortality. 
Funding 
Joint Global Health Trials (Medical Research Council, Department for International Development, 
Wellcome Trust).  
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Introduction 
Despite antiretroviral therapy (ART), early mortality among HIV-positive people with advanced 
disease remains unacceptably high in low- and middle-income countries.1 Tuberculosis is 
consistently identified as the leading cause of death among HIV-positive people, and is often 
undiagnosed prior to death.2 Diagnostic tests for tuberculosis remain unsatisfactory; no available 
test which is logistically feasible for point-of-care use in primary-level healthcare clinics (PHCs) has 
adequate sensitivity for use among HIV-positive people, particularly those with advanced disease. As 
a consequence, empirical tuberculosis treatment, meaning treatment without bacteriological 
confirmation, is common.3-5 Empirical tuberculosis treatment generally requires a physician’s 
decision,6 but in many primary care settings physicians are not easily accessible. The process of 
investigating for tuberculosis may therefore be slow, and may delay ART initiation.7 
Wider use of empirical tuberculosis treatment has been discussed;8 advantages include rapid 
initiation of tuberculosis treatment, with potential mortality benefits for those with active 
tuberculosis, and protection against reactivation of latent tuberculosis for those without active 
tuberculosis. Disadvantages, for those without active tuberculosis, include drug toxicity, drug 
interactions, increased pill burden, and, potentially, failure to identify and treat other co-
morbidities.8 
South African guidelines in 2010 recommended ART initiation for HIV-positive people in World 
Health Organization (WHO) stage 3 or 4, or CD4≤350 cells per µL, with "fast-track" (within two 
weeks) initiation for people with CD4 counts <100 cells per µL. The need for symptom screening, 
and, if symptomatic, investigation, for tuberculosis prior to initiating ART was emphasised. The first-
line test for tuberculosis was sputum smear microscopy, progressively replaced by Xpert MTB/RIF, 
rolled out nationally between 2011 and 2013. ART start was recommended within two to four weeks 
of tuberculosis treatment initiation. From March 2013, fast-track (within seven days) ART initiation 
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was recommended for all HIV-positive people with CD4<200 cells per µL, and those with tuberculosis 
with CD4<50 cells per µL. 
We hypothesised that a management algorithm which allowed nurses to triage HIV-positive patients 
with advanced immunosuppression, identify those with the highest probability of tuberculosis, and 
start tuberculosis treatment immediately, followed by ART, would reduce early mortality. We 
reasoned that this reduction in mortality would be achieved by two mechanisms: first, by reducing 
the number of people with active tuberculosis who remained untreated; second, by removing delays 
associated with investigation for tuberculosis, we assumed that time to ART initiation would be 
reduced in all patients (including those treated for tuberculosis), with an additional mortality 
benefit.9  
We designed a “TB triage tool” to enable nurses to assess tuberculosis risk, using measures which 
can give an in-session result in a primary care setting. A candidate component of our TB triage tool 
was an assay for mycobacterial lipoarabinomannan (LAM), commercially available as a urine-based 
point-of-care lateral flow assay (DetermineTM TB LAM, Alere Inc, Waltham, USA). However, it is too 
insensitive to be used alone as a screening test,10,11 and other measures were needed to increase 
triage tool sensitivity. Haemoglobin and body mass index (BMI) are consistently associated with risk 
of mortality among HIV-positive people, and risk of active tuberculosis.12-14 We constructed a clinical 
algorithm based on this TB triage tool (figure 1; appendix page 1), to allow nurses to assess HIV-
positive patients with advanced disease, and guide them to start tuberculosis treatment 
immediately, followed by ART two weeks later (in line with national guidelines) for those in the 
highest probability category; start ART immediately for those in the lowest probability category; and 
arrange further investigation for those with medium probability, with review within one week so 
that tuberculosis treatment or ART could be started promptly. 
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The aim of the TB Fast Track trial was to determine whether patients with advanced HIV disease 
managed according to this clinical algorithm experienced lower six-month mortality than those 
managed according to routine clinic practice.  
Methods 
Study design and participants  
The TB Fast Track trial was a pragmatic, unmasked, parallel, two-arm cluster-randomised controlled 
trial (methods described previously;15 protocol available: https://doi.org/10.17037/PUBS.04653158 ). 
Because the intervention was a management strategy involving assessment of risk of active 
tuberculosis, we thought it likely that individual randomisation would result in “contamination” 
among standard of care (control) arm participants, i.e. that study implementation would alter their 
clinical management substantially, compared to routine care. After obtaining approval from district 
health staff and clinic managers, we therefore randomised clusters rather than individuals, where 
clusters comprised PHCs in Gauteng, Limpopo, and North-West provinces in South Africa. Eligible 
PHCs delivered both ART and tuberculosis treatment, had ART initiation rates estimated to be high 
enough to produce enough study participants, and did not have on-site tuberculosis testing facilities; 
Xpert MTB/RIF (performed at off-site laboratories) became the first-line test for tuberculosis at all 
clinics during the course of the trial. In most PHCs a doctor was available for morning sessions 3-5 
days per week.  
Adults (aged ≥18 years) with a recorded HIV-positive test result were eligible if they had a CD4 count 
≤150 cells per µL, and had not taken ART in the previous six months, or tuberculosis treatment in the 
previous three months. We excluded adults at higher risk of adverse events from tuberculosis 
treatment, specifically those reporting chronic liver disease, or alcohol intake exceeding 28 units 
(men) or 21 units (women) per week; those with danger signs necessitating urgent referral to 
secondary care, based on WHO guidelines;6 and those planning to leave their clinic catchment area 
within six months. South African guidelines effective at study initiation recommended that women in 
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the first trimester of pregnancy should not take efavirenz-based ART. Women of child-bearing 
potential were therefore initially required to have a negative pregnancy test to be included. After 
this caution was removed from guidelines, from July 2013 enrolment was open to all women 
regardless of child-bearing potential. Study staff offered enrolment to all eligible participants until 
the required sample size for each clinic was reached. 
 
 The research ethics committees of the University of the Witwatersrand and the London School of 
Hygiene & Tropical Medicine, and the South African Medicine Controls Council approved the study. 
All participants gave written or witnessed verbal informed consent. An independent Trial Steering 
Committee and Data Monitoring Committee provided trial oversight.  
Randomisation and masking 
In August 2012, a statistician randomised 20 PHCs  in a ratio of 1:1  to intervention or control arms, 
based on restriction to achieve reasonable balance, separately, for mean CD4 count, peri-urban 
versus rural clinic location, and total monthly ART initiations. The random allocation was selected at 
a public ceremony involving clinic representatives.15 Early participant recruitment was slower than 
anticipated, and therefore in October 2013 we randomised four additional PHCs, giving a total of 24 
clusters; we considered these additional four clinics as a separate stratum in the analysis. 
Procedures 
In intervention clinics, study nurses assessed participants including tuberculosis symptom screening, 
based on the WHO screening tool (any of cough, weight loss, night sweats, or fever);16 measurement 
of height and weight to determine BMI; haemoglobin estimation based on a finger-prick blood 
sample (Hemocue 201+, Hemocue, Angelholm, Sweden); and estimation of urine LAM using the 
lateral flow assay according to manufacturer’s instructions (DetermineTM TB LAM, as above).  Study 
nurses then used the study algorithm (figure 1) to classify participants as high probability of 
tuberculosis if the urine LAM assay was positive (band of intensity grade 1 or above, as 
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recommended by the company until January 2014), BMI was less than 18·5 kg/m2 or haemoglobin 
was less than 100 g/L; medium probability if they had no high probability criteria but one or more 
tuberculosis symptoms; or low probability if they had no high probability criteria and reported no 
tuberculosis symptoms. For participants classified as high probability, study nurses facilitated the 
start of tuberculosis treatment as soon as possible, with ART initiation two weeks later, in line with 
national guidelines, unless there was a contraindication. Those classified as low probability started 
ART as soon as possible. Those classified as medium probability were further assessed in line with 
national guidelines for management of sputum smear-negative tuberculosis with chest radiography, 
sputum for smear and mycobacterial culture (or Xpert MTB/RIF, as it became available), and/or a 
course of antibiotics, as clinically appropriate. Study staff reviewed medium probability participants 
within a week wherever possible, aiming to start tuberculosis treatment or ART at that point.   
For intervention arm participants, at enrolment, research staff collected a single spot sputum sample 
for smear, mycobacterial culture, organism identification, and sensitivity testing for isoniazid and 
rifampicin; these results were fed back to clinic staff. We intended this sample to provide a minimum 
reference standard to indicate which participants had active tuberculosis, acknowledging that this 
would have suboptimal sensitivity. Research staff did not collect sputum specimens from control 
arm participants, as this was not standard of care. After LAM testing, residual urine was frozen at -
80°C for mycobacterial culture at the end of the study.  
Study staff reviewed intervention arm participants to facilitate early management according to the 
study algorithm; clinic staff delivered subsequent HIV care (and tuberculosis treatment, if initiated) 
according to their usual practice.  
 
In standard of care clinics, study staff enrolled participants and collected a urine sample which was 
frozen and cultured for mycobacteria at the end of the study; all subsequent care was by clinic staff.  
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For all participants in both study arms, laboratory monitoring was per South African guidelines; liver 
function tests were not routinely performed, and there were no laboratory evaluations for study 
purposes after the enrolment visit. Six months after enrolment, all participants were reviewed by 
study nurses, in person where possible, to capture information relevant to study outcomes.   
Outcomes 
The primary outcome was all-cause mortality at six months after study enrolment, defined as a 
known death before six months, or known to be alive after 150 days, based on reports from 
participant-nominated contacts and clinic staff, and data from South African vital status registration. 
We defined outcomes at six months because the highest risk of death was expected to be in the first 
three months and because, by six months, participants who started tuberculosis treatment as part of 
the intervention would be nearing tuberculosis treatment completion. Secondary outcomes, 
ascertained by self-report or record review, were hospitalisation within six months after enrolment; 
time from enrolment to ART initiation (within six months); a binary outcome of whether ART was 
started within 30 days of enrolment; retention in HIV care at six months (defined as any HIV-related 
visit between four and eight months after enrolment); and adverse events. All-cause 12-month 
mortality was pre-specified as an exploratory outcome. All outcomes were measured at the 
individual level. 
Research staff undertook case note reviews at two and six months, and conducted a study visit at six 
months, to determine vital status; tuberculosis treatment and ART start dates; and hospitalisation 
and other important events.  To ascertain possible serious and severe (grade 3 or 4) adverse events 
in specified categories relevant to the intervention (specifically hepatotoxicity, hypersensitivity, 
peripheral neuropathy, optic neuritis, and nephrotoxicity), research nurses and research assistants 
enquired about symptoms and history suggesting possible adverse events at every study visit, 
including early study review visits for intervention arm participants, and sought relevant data in case 
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note reviews. Given that, in line with the pragmatic design, there were no equivalent early study 
visits for control arm participants, we anticipated that  adverse events would be more completely 
ascertained in the intervention arm. 
Study clinicians classified adverse events, using conventional criteria,17 after detailed review of all 
available research and routine data, including hospitalisation records, and assigned relationship to 
the intervention based on likelihood of association with empirical tuberculosis treatment. .  
As part of a sub-study, reported separately, where possible we conducted minimally-invasive 
autopsies on study participants who died.18 An independent panel assigned causes of death, based 
on clinical information from this study along with health facility and autopsy data, where available, 
to decedents who also had verbal autopsy data available.19 
Statistical analysis 
Sample size calculations are detailed elsewhere.15 Briefly, assuming ten clinics per arm, a harmonic 
mean of 175 participants per clinic, 5% with unknown vital status at six months, a mortality of 25 per 
100 person-years (pyrs) in the standard of care arm, and coefficients of variation of 0·2 and 0·25, 
there would be 91% and 85% power to assess a 40% reduction in mortality, respectively. If the 
coefficient of variation was 0·2, there would be 81% power to assess a 35% reduction in mortality. 
Six months into enrolment, due to slower than anticipated recruitment, we reassessed sample size 
calculations. Assuming a harmonic mean of 109 participants per clinic, by randomising an additional 
four clinics, the study maintained similar power and effect sizes as with the original calculation.  
 
As described previously,15 we based analysis on a cluster-level approach, appropriate for the small 
number of clusters. For rate or binary outcomes, we calculated the overall rate (or risk) for each 
cluster. We calculated the rate ratio as the geometric mean of cluster-level rates in the intervention 
divided by control arm, taking into account the stratified randomisation. We calculated the standard 
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error for each log(effect measure) by regressing the log(rate) on the study arm, strata, and their 
interaction. We based the 95% confidence interval (CI) and p-value on 20 degrees of freedom. We 
conducted adjusted analyses if, after visual inspection, we observed imbalance by study arm in 
individual-level factors, using methods for a small number of clusters.  
We conducted pre-specified subgroup analyses for the primary outcome for baseline CD4 count (<50 
or ≥50 cells per μL), self-reported tuberculosis history (no previous or previous tuberculosis), 
baseline BMI (<18·5 or ≥18·5 kg/m2), and baseline haemoglobin (<80 or ≥80 g/L). The study was not 
powered to detect differences in these subgroups. In two post hoc  sensitivity analyses for the 
primary outcome, i) we assumed those with unknown vital status at six months  had died, with date 
of death the midpoint between date last known alive and six months after enrolment; and  ii) we 
excluded two control clusters in which more than 25% of participants self-reported taking IPT at 
enrolment. 
Role of the funding source 
The funder played no role in study design, implementation, data collection, analysis, or decision to 
publish. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results 
Between 19 December 2012 and 18 December 2014 we screened 3091 people; 26 declined 
enrolment, 12 were ineligible, and 3053 were enrolled (figure 2). 31 participants were subsequently 
excluded, leaving 3022 (1507 intervention, 1515 control) in the analysis. The median age was 37 
years, 55·2% were female and the median CD4 count was 72 cells per µL (table 1). Baseline variables 
were similar by study arm except that participants in the intervention arm were more likely to report 
one or more symptoms compatible with tuberculosis (72·7% intervention versus 65·7% control); to 
report having had tuberculosis tests done in the six months prior to enrolment (48·9% intervention 
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versus 42·7% control); and less likely to be taking isoniazid preventive therapy (IPT; 3·4% 
intervention versus 10·4% control). This difference in IPT use was attributable to two control clusters 
where more than 20% of participants reported taking IPT at enrolment.  
In the intervention arm, study nurses used the algorithm to assign 689 (45·7%) participants to the 
high probability category, 475 (31·5%) to medium, and 342 (22·7%) to low probability of tuberculosis 
(data missing for one participant; baseline characteristics by category shown in appendix page 2; 
intersection between algorithm components shown in appendix pages 9-11). In the 14 days after 
enrolment, based on record review, 23·9% control arm participants either gave a sputum sample 
(17·5%, among whom 195/264 [73·9%] had an Xpert MTB/RIF result recorded) or had a chest 
radiograph performed (8·6%); investigation was slightly more frequent among those reporting one 
or more symptoms at enrolment (sputum 19·7%, chest radiograph request 10·5%, either 27·3%) 
versus those who reported no symptoms (sputum 13·3%, chest radiograph request 5·0%, either 
17·5%). Overall, 930/1507 (61·7%) intervention arm participants had started tuberculosis treatment 
by 60 days after enrolment compared with 172/1515 (11·4%) in the control arm (appendix page 12).  
The total follow-up time was 1404 person-years. Vital status at six months was determined for 98·7% 
intervention and 98·0% standard of care arm participants. The mortality rate was 19·0 (134 
deaths/704 pyrs) in the intervention versus 21·6 (151/699 pyrs) per 100 pyrs in the control arm 
(unadjusted hazard ratio [HR] 0·92, 95% CI 0·67–1·26; adjusted HR 0·87, 95% CI 0·61–1·24, p=0·41, 
table 2, figure 3, appendix page 3). In a post hoc sensitivity analysis, assuming those with unknown 
vital status at six months (n=50; 19 intervention, 31 control) had died, the adjusted HR was 0·86 
(95% CI 0·61–1·21, p=0·37). Prespecified subgroup analyses for CD4 and BMI strata gave similar 
results for the intervention effect on mortality (appendix page 4). Estimation of the intervention 
effect for those with previous tuberculosis and by haemoglobin category was not possible because 
when data were restricted to these subgroups, six and five clinics respectively had no deaths. The 
coefficient of variation for the primary outcome in all clusters was 0·09. In a post hoc sensitivity 
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analysis, excluding the two control clusters in which more than 25% of participants self-reported 
taking IPT at enrolment, the effect estimates for the primary outcome were similar: unadjusted HR 
0·95, 95% CI 0·68-1·32; p=0·75 and adjusted HR 0·88, 95% CI 0·61-1·28; p=0·50. The 12-month 
mortality rate was 13·1 (178 deaths/1314 pyrs) in the intervention versus 14·7 (187/1269 pyrs) per 
100 pyrs in the control arm (unadjusted HR 0·97, 95% CI 0·75–1·25; adjusted HR 0·92, 95% CI 0·69–
1·24, p=0·57, appendix page 5).  
The risk of hospital admission over the six-month follow-up period was similar by arm: 13·3% 
(201/1507) and 10·4% (158/1515) in the intervention and control arms, respectively, adjusted risk 
ratio (RR) 1·11 (95% CI 0·89–̶1·38, p=0·34, table 2). In the intervention versus control arm, a lower 
percentage of participants started ART within 30 days of enrolment (66·4% [1001/1507] versus 
72·9% [1104/1515]), though there was no statistical evidence for a difference by arm (adjusted RR 
0·91, 95% CI 0·79–1·05, p=0·17, figure 3B). The median time to ART start was 21 (interquartile range 
[IQR] 14–39) days in the intervention versus 13 (IQR 6–31) days in the control arm; in the control 
arm, the median time to ART start was no different among participants who did versus did not 
report one or more tuberculosis symptoms at enrolment (median [IQR] 13 [6-29] vs. 13 [6-31] days 
respectively). The incidence rate of starting ART within six months of enrolment was 30% lower in 
the intervention versus standard of care arm (adjusted HR 0·69, 95% CI 0·46–1·04, p=0·07) though 
the 95% CI included one; however by six months, the proportion of participants who had started ART 
was no different by arm (88·8% versus 88·9% for intervention versus control; outcome not pre-
specified). Among participants who started tuberculosis treatment followed by ART, the median 
time between tuberculosis treatment start and ART start was 19 days (IQR 14–32, n=820) in the 
intervention arm versus 25 days (IQR 15–49, n=131) in the control arm. Retention in HIV care was 
similar by study arm: 934/1507 (62·0%) intervention versus 945/1515 (62·4%) control, adjusted RR 
1·02 (95% CI 0·83–1·24). Among 774 intervention arm participants who started tuberculosis 
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treatment within 60 days of enrolment (thus likely attributable to the intervention), 85·0% were still 
on tuberculosis treatment 168 days after tuberculosis treatment start.  
Table 3 shows serious or severe adverse events, in the pre-specified study categories, that were 
detected by self-report at study visits and/or by record review. 38 participants (28 intervention, ten 
control) reported 40 serious or severe adverse events in study-defined categories. Grade 3/4 nausea 
and vomiting was the category of event most commonly reported (ten intervention, four control); 
followed by symptoms which could indicate peripheral neuropathy at grade 3 or above (eight 
intervention, two control); and grade 3 or above skin rash (six intervention, two control). Abnormal 
liver function tests were recorded in clinic records in four intervention and three control 
participants. In the intervention arm, 19 of 29 adverse events occurred at least one day after the 
start of tuberculosis treatment (median 21, range 1–165). In the intervention versus control arm, six 
versus two adverse events were recorded to have a fatal outcome. Following review, among six 
deaths in the intervention arm, none appeared to be attributable to the study intervention (see 
appendix pages 6-8 for further details). Among intervention arm decedents who underwent 
minimally-invasive autopsy, 0/17 had fulminant hepatitis.18  
970/1507 (64·4%) intervention arm participants produced a sputum specimen for mycobacterial 
culture, among which 36/1507 (2·4%) were smear positive and 102/1507 (6·8%) were culture-
positive for Mycobacterium tuberculosis (classifying participants who could not produce sputum as 
smear- and culture-negative). Eight participants had stored urine which was M. tuberculosis culture 
positive at the end of the study (seven intervention, one control); of the seven in the intervention 
arm, four had a bacteriologically-positive sputum result at enrolment (three culture positive, one 
smear positive but culture negative; the remaining three were unable to provide sputum). The 
proportions of intervention arm participants with a positive sputum culture by study algorithm-
assigned probability of tuberculosis were 11·2%, 4·0% and 1·8% in the high, medium, and low 
probability categories, respectively. The overlap between sputum smear and culture positivity and 
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urine LAM positivity is shown in appendix page 13. Among 102 participants with M. tuberculosis 
cultured from sputum, four (3·9%) isolates were isoniazid monoresistant, and one (1·0%) was 
resistant to both isoniazid and rifampicin. 
Six-month mortality among intervention arm participants assigned to high, medium, and low 
probability of tuberculosis was 14·2%, 5·5%, and 2·9% respectively (appendix page 14); this 
compared to 14·6%, 7·4%, and 3·7% for control participants when probabilities were applied 
retrospectively based on LAM testing of stored urine and haemoglobin estimation from routine 
records, when available (n=1039, appendix page 15).  
Discussion 
Our study triage tool successfully identified individuals who were at higher risk of tuberculosis and of 
mortality, and our study algorithm resulted in much higher coverage of tuberculosis treatment in the 
intervention compared to control arm. However, the intervention did not reduce mortality or 
improve other clinical outcomes. The large anticipated effect size depended on the assumption that 
the intervention would, firstly, reduce tuberculosis-specific mortality by increasing coverage of 
tuberculosis treatment to individuals with active tuberculosis that would not be detected in routine 
practice, and, secondly, reduce all-cause mortality by accelerating ART initiation. In practice, the 
intervention did not accelerate ART initiation compared to the control arm, and we found that a 
substantial increase in coverage of tuberculosis treatment did not result in the large reduction in 
mortality that the trial was powered to detect.  
Possible explanations for the lack of mortality benefit include that that tuberculosis was not a major 
cause of mortality. This would be inconsistent with evidence from autopsy studies;2 furthermore, in 
a small subset of deaths (n=34) among study participants where minimally-invasive autopsy was 
performed, almost half had prevalent tuberculosis.18 Among 259 decedents included in a sub-study 
validating verbal autopsy, 69 (26·6%) were assigned tuberculosis as cause of death by an 
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independent panel.19 It seems unlikely that the intervention increased mortality due to unnecessary 
tuberculosis treatment, given the low number of recorded serious and severe adverse events, or 
that the intervention effect was undermined by undetected drug-resistant tuberculosis, given the 
low prevalence of drug-resistant tuberculosis among intervention arm participants. However over 
40% participants in both study arms reported undergoing tuberculosis tests as part of their routine 
care in the six months prior to enrolment; around 30% in both arms were recorded to have had a 
sputum test in the 28 days prior to enrolment, substantially higher than our pilot work suggested, 
possibly reflecting increased awareness of tuberculosis as a result of Xpert MTB/RIF roll-out, or study 
activities, or both. This could have reduced the prevalence of active tuberculosis among the enrolled 
population, especially later in the study as Xpert MTB/RIF; the intervention might have a larger 
effect in populations where there was less tuberculosis investigation prior to ART initiation.  
The lack of mortality benefit could be partly explained by the intervention's failure to accelerate ART 
initiation. The major reason for slower ART initiation in the intervention versus control arm was the 
high proportion (62%) of intervention participants starting tuberculosis treatment, combined with 
faster than expected ART initiation in the control arm. Intervention arm participants given empirical 
tuberculosis treatment were intended to start ART two weeks later, but in practice the median time 
to start ART after tuberculosis treatment among intervention arm participants was 19 days, slightly 
shorter than observed among control arm participants (median 25 days). We do not have detailed 
data to explain why ART initiation was slower than planned. In some cases there were 
understandable explanations for delay, such as abnormal renal function, but often the reason was 
unclear. Our impression was that some clinic staff were reluctant to start ART in people who were 
perceived to be unwell; further work to understand and correct misconceptions may be needed, and 
this is particularly relevant in the context of efforts to accelerate ART initiation. The presence of the 
study team in control clinics might have had an unplanned effect to speed up ART initiation; the 
median time from enrolment to ART initiation in the TB Fast Track control arm was 13 days 
 18 
compared to 25 days in a pilot study in 21 study clinics in 2011;7 secular change may also have 
contributed. It seems unlikely that the overall one-week difference in time to ART initiation in our 
intervention versus control arm would account for a large difference in six-month mortality; 
however, our assumption that empirical tuberculosis treatment would have an overall effect to 
accelerate ART initiation proved incorrect. Thus our intervention, in practice, comprised much higher 
coverage of tuberculosis treatment, without any additional benefit from earlier ART, and the 
observed intervention effect likely reflects this.  
Time to ART initiation among control arm participants was the same for the 67% who reported 
symptoms consistent with tuberculosis compared to the 33% who did not. Thus, in the control arm, 
any investigation or treatment for active tuberculosis did not delay ART initiation. This may be partly 
explained by the unexpectedly high frequency of investigation for tuberculosis prior to enrolment. 
Nonetheless, symptomatic individuals should have had sputum sent for mycobacterial culture (or, as 
it was rolled out, Xpert MTB/RIF if not previously sent); in the 14 days after enrolment only 20% 
symptomatic control arm participants were recorded to have had a sputum sample sent. These data 
suggest that any adverse outcomes attributable to early ART start without comprehensive 
tuberculosis investigation among symptomatic control arm participants were not outweighed by 
empirical tuberculosis treatment in the intervention arm, suggesting that guidelines may 
overemphasise the requirement to delay ART start until active tuberculosis has been excluded. 
Strategies for rapid ART initiation among symptomatic people with advanced HIV disease merit 
further evaluation. 
The REMEMBER trial similarly addressed the mortality benefit of empirical tuberculosis treatment.20 
The trial showed no benefit of empirical tuberculosis treatment compared to IPT, in a selected 
population with CD4 counts less than 50 cells per µL, and no evidence of tuberculosis based on 
clinical presentation and initial investigation, which included chest radiography in 65% and Xpert 
MTB/RIF in around 91%.20 The PROMPT trial individually randomised individuals in four countries in 
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Africa with CD4 less than 50 cells per µL and no evidence of tuberculosis on sputum smear or chest 
radiography to presumptive tuberculosis treatment or control; it was stopped early because of slow 
recruitment.21 The STATIS trial found no difference in death or invasive bacterial disease by 24 weeks 
among adults with CD4 <100 cells per µL individually randomised to ART plus extensive tuberculosis 
investigation versus ART and empirical tuberculosis treatment.22 The LAM assay is feasible for PHC-
level use but, as elsewhere, its sensitivity in our study was too low to be used in isolation.23 New, 
high-sensitivity LAM assays hold promise if they can be formulated for point-of-care use in PHCs. 
Strengths of the TB Fast Track trial include its pragmatic design, with broad inclusion criteria, 
maximising generalisability. The intervention algorithm was based on existing, low-cost measures 
and delivered by nurses, who were integrated into routine PHC care. Completeness of follow-up was 
excellent. Some limitations of the trial are consequent on its pragmatic design. We performed few 
non-routine investigations, and thus have limited information from which to determine which 
participants genuinely had tuberculosis at enrolment, and what caused death. We minimised study-
specific follow-up visits, to approximate how the intervention would be delivered in routine 
conditions. This meant that adverse events were under-ascertained in both arms; additional visits to 
implement the study algorithm for most participants in the intervention arm likely resulted in more 
complete recording of possible adverse events in the intervention versus control arm. However, 
ascertainment of deaths was very high in both arms, and thus we can be confident that fatal adverse 
events did not outweigh any benefit of the intervention. Hospital admissions may have been under-
ascertained in control clinics because of fewer study visits and less interaction with study staff. It is 
also possible that intervention arm participants had a higher probability of referral to hospital 
because of increased contact with research and clinic staff.  
The TB Fast Track intervention enabled nurses in PHCs to identify HIV-positive adults at high risk of 
tuberculosis and of death, and achieved high coverage of empirical tuberculosis treatment. 
However, the intervention did not result in the large mortality benefit which the trial was powered 
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to detect. People presenting for care with advanced HIV disease need a package of care in which 
tuberculosis diagnosis and treatment are a key component. More sensitive, rapid tuberculosis 
diagnostic tests suitable for use by nurses in primary care clinics are urgently needed so that people 
with tuberculosis can be correctly identified and promptly treated. Strategies for rapid ART initiation 
among symptomatic people with advanced HIV disease merit further evaluation. 
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Research in context panel 
Evidence before this study 
Prior to undertaking the study, we searched Medline and Embase to December 2010 using the terms 
(presumptive or empiric*) adj3 (treatment or therap*) AND AIDS or HIV or acquired 
immunodeficiency syndrome AND TB or tuberculosis. We also searched "Africa wide information" 
using equivalent terms, and clinical trials databases. These searches yielded no relevant studies. 
Since then, the REMEMBER trial similarly addressed the mortality benefit of empirical tuberculosis 
treatment, in an individually-randomised trial. The trial showed no benefit of empirical tuberculosis 
treatment compared to IPT, in a selected population with CD4 counts less than 50 cells per µL, and 
no evidence of tuberculosis based on clinical presentation and initial investigation, which included 
chest radiography in 65% and Xpert MTB/RIF in around 91%. The PROMPT trial individually 
randomised individuals in four countries in Africa with CD4 less than 50 cells per µL and no evidence 
of tuberculosis on sputum smear or chest radiography to presumptive tuberculosis treatment or 
control; it was stopped early because of slow recruitment. The STATIS trial found no difference in 
death or invasive bacterial disease by 24 weeks among adults with CD4 <100 cells per µL individually 
randomised to ART plus extensive investigation for tuberculosis versus ART and empirical 
tuberculosis treatment. 
Added value of this study 
This is the first trial to test an algorithm enabling nurses to initiate empirical tuberculosis treatment 
in primary healthcare centres using point of care diagnostic tests. The intervention resulted in high 
coverage of tuberculosis treatment but did not accelerate ART initiation. There was no difference in 
mortality at six months between participants in the intervention versus control arms. The 
intervention was designed to use simple, currently-available point-of-care measures to guide 
empirical tuberculosis treatment, and thus to be feasible to implement in low-income settings.  
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Implications of all the available evidence 
Accumulating evidence suggests that HIV-positive adults with advanced disease are unlikely to 
experience a large mortality benefit from untargeted empirical TB treatment. More sensitive TB 
diagnostic tests suitable for use by nurses in primary healthcare clinics in low-income settings 
remain a key priority. 
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Figures and tables 
Figure 1: TB Fast Track intervention management algorithm 
 
ART=antiretroviral therapy. BMI=body mass index. Hb=haemoglobin. LAM=urine 
lipoarabinomannan. TB=tuberculosis.  
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Figure 2: Trial profile 
 
ART=antiretroviral therapy. min=minute. TB=tuberculosis  
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Figure 3A: Kaplan-Meier curves showing time from enrolment to death by study arm   
 
 
Figure 3B: Kaplan-Meier curves showing time from enrolment to ART start by study arm 
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Table 1: Baseline characteristics of the study population, by study arm (n=3022) 
  Intervention 
(n=1507) 
Control 
(n=1515) 
Sex, female n (%) 820 (54·4%) 849 (56·0%) 
Age, years Median (IQR) 37 (32–44) 36 (31–43) 
CD4*, cells per µL Median (IQR) 73 (35–111) 70 (35–113) 
CD4* <50 cells per µL n (%) 508 (33·7%) 521 (34·4%) 
BMI† Median (IQR) 21·2 (18·8–24·7) 21·6 (19·2–24·8) 
BMI† <18.5 kg/m2 n (%) 320 (21.·2%) 271 (17·9%) 
Haemoglobin‡ <100 g/L n (%) 428 (28·4%) 322 (29·8%) 
Urine LAM positive§  n (%) 181 (12·0%)  222 (15·2%) 
≥ one TB symptom¶ n (%) 1095 (72·7%) 993 (65·7%) 
Previous TB|| n (%) 151 (10·0%) 136 (9·0%) 
Taking IPT** n (%) 51 (3·4%) 158 (10·4%) 
Taking co-trimoxazole†† n (%) 691 (45·9%) 718 (47·4%) 
TB tests in last 6 months 
(self-reported)‡‡ 
n (%)  737 (48·9%) 645 (42·7%) 
Sputum test sent in 28 days 
prior to enrolment (record 
review) 
n (%) 471 (31·3%) 412 (27·2%) 
 Among those who 
had sputum sent, Xpert 
MTB/RIF result recorded 
n (%) 357/471 (75·8%) 321/412 (77·9%) 
Chest radiograph performed 
in 28 days prior to 
enrolment (record review) 
n (%) 79 (5·2%) 38 (2·5%) 
 
* Missing data for one participant in the intervention arm. † Missing data for three participants in 
the control arm. ‡ Missing data for one participant in the intervention arm and 435 participants in 
the control arm. § Missing data for two participants in the intervention arm and 52 participants in 
the control arm. ¶ Missing data for one participant in the intervention arm and four participants in 
the control arm. || Missing data for one participant in the intervention arm. ** Missing data for one 
participant in each of the intervention and control arms. †† Missing data for one participant in each 
of the intervention and control arms. ‡‡ Missing data for one participant in the intervention arm and 
six participants in the control arm. 
 
IQR=interquartile range.  BMI=body mass index.  LAM=lipoarabinomannan. TB=tuberculosis. 
IPT=isoniazid preventive therapy. 
TB symptoms defined as any of cough, fever, unintentional weight loss, night sweats. 
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Table 2: Effect of the intervention on primary and secondary outcomes 
 Intervention Control       
Primary outcome Rate/100 py 
(deaths/py) 
Rate/100 py 
(deaths/py) 
Unadjusted HR 95% CI P-value Adjusted 
HR* 
95% CI P-value 
Mortality rate over 6 
months 
19·0 
(134/704) 
21.6  
(151/699) 
0.92 (0.67, 1.26) 0.58 0.87† 
 
(0.61, 1.24) 0.41 
 
Rate/100 py 
(deaths/py) 
Rate/100 py 
(deaths/py) 
Unadjusted RD 95% CI P-value Adjusted 
RD* 
95% CI P-value 
 19·0 
(134/704) 
21.6  
(151/699) 
-2.14 (-7.76, 3.49) 0.44 -2.19† 
 
(-5.43, 1.05) 0.17 
Secondary outcomes % (n/N) % (n/N) Unadjusted RR 95% CI P-value Adjusted 
RR* 
95% CI P-value 
Hospital admission over 6 
months 
13·3% 
(201/1507) 
10·4% 
(158/1515) 
1·19 (0·94–1·50) 0·14 1·11 
 
(0·89–1·38) 0·34 
Retention in care by 6 
months 
62·0% 
(934/1507) 
62·4% 
(945/1515) 
1·01 (0·82–1·23) 0·94 1·02‡ (0·83–1·24) 0·87 
Started ART within 30 days 
of enrolment 
66·4% 
(1001/1507) 
72·9%  
(1104/1515) 
0·89 (0·76–1·04) 0·13 0·91§ (0·79–1·05) 0·17 
 
Rate/100 py 
(deaths/py) 
Rate/100 py 
(deaths/py) 
Unadjusted HR 95% CI P-value Adjusted 
HR* 
95% CI P-value 
Rate of starting ART by 6 
months 
834·5 
(1338/160·3) 
1034 
(1347/130·3) 
0·68 (0·41–1·15) 0·14 0·69¶ (0·46–1·04) 0·07 
Post hoc analysis % (n/N) % (n/N) Unadjusted RR 95% CI P-value Adjusted 
RR* 
95% CI P-value 
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Risk of starting ART by 6 
months 
88·8% 
(1338/1507) 
88·9% 
(1347/1515) 
0·99 (0·94–1·04) 0·75 1·0¶ (0·95–1·04) 0·84 
HR=hazard ratio. RD=rate difference. RR=risk ratio. CI=confidence interval. ART=antiretroviral therapy. py=person-years. 
 
* Analyses adjusted for sex, age, BMI, CD4, taking IPT at baseline, TB symptoms, TB tests on last 6 months, previously treated for TB and 
randomisation strata. Analysis of time to starting ART also adjusted for follow-up time. All adjusted analyses included 3009 participants (1504 
intervention and 1505 control). † Includes 284 deaths (134 in intervention and 150 in control). ‡ Includes 1872 outcomes (932 in intervention 
and 940 in control). § Includes 2098 outcomes (999 in intervention and 1099 in control). ¶ Includes 2677 outcomes (1336 in intervention and 
1341 in control).  
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Table 3: Serious and severe adverse events detected by self-report and record review, by 
study arm 
  Intervention Control 
Number of events (# participants)  29 (28) 11 (10) 
Age in years, median (range)  35 (22–52) 39 (30–55) 
Sex, n (%) female  14 (50%) 4 (40%) 
CD4 at enrolment in cells per µL, 
median (range) 
 68 (4–143) 50·5 (21–142) 
Type, n (%) Nausea/vomiting† 10 (33%) 4 (36%) 
Suspected peripheral neuropathy 8 (27%) 2 (18%) 
Skin rash/hypersensitivity 6 (20%) 2 (18%) 
Abnormal liver function 
tests/hepatitis 
4 (13%) 3 (27%) 
Other* 1 (7%) 0 
Days from enrolment to onset of AE Median; IQR 
range 
26; 13–79 
0–169 
29; 8–109 
7–166 
AE occurred after ART start‡, n (%) At least one day after 
Before/same day as ART start 
Did not start ART 
14 (48%) 
12 (41%) 
3 (10%) 
5 (45%) 
3 (27%) 
3 (27%) 
Days from starting ART to AE, 
restricted to AEs after ART  
Median; range  
n 
53·5; 3–162 
14 
103; 18–144 
5 
AE occurred after TB start‡, n (%) At least one day after 
Before/same day as TB start 
Did not start TB treatment 
19 (66%) 
4 (14%) 
6 (21%) 
5 (45%) 
1 (9%) 
5 (45%) 
Days from starting TB treatment to 
AE, restricted to AEs after TB 
Median; range  
n 
21; 1–165 
19 
14; 5–125 
5 
Outcome of AE, n (%) Resolved 
Resolved with sequelae 
Ongoing  
Fatal† 
15 (52%) 
1 (3%) 
7 (24%) 
6 (21%) 
8 (73%) 
0 
1 (9%) 
2 (18%) 
Relationship with intervention, n(%) Not associated 
Probably not associated 
Possibly associated 
Probably associated  
Definitely associated† 
9 (31%) 
1 (3%) 
7 (24%) 
8 (28%) 
4 (14%) 
11 (100%) 
0 
0 
0 
0 
 
*generalised body weakness  
† One adverse event of nausea/vomiting (see appendix page 7: AE5) is recorded as definitely associated with a 
fatal outcome because there was no documentation of resolution. The patient was lost to follow-up from TB 
treatment, subsequently admitted to hospital with vomiting and diarrhoea and died 48 days post-enrolment. 
Hospital-assigned cause of death was meningitis and renal failure. Autopsy: Mycobacterium tuberculosis (sensitive 
to isoniazid and rifampicin) isolated from liver and spleen but not cerebrospinal fluid. Panel-assigned cause of 
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death was disseminated TB. Therefore, the adverse event (nausea and vomiting) was considered associated, but 
death was considered not associated with the intervention. 
 
‡  33/38 participants started ART (8/10 in control arm and 25/28 in intervention arm); 28/38 started TB treatment 
(5/10 in control arm and 23/28 in intervention arm). 
 
Two participants reported two AEs each; one in the control arm – both events (abnormal liver function 
tests/hepatitis and nausea/vomiting) occurred 5 days after starting TB treatment (patient did not start ART); one in 
the intervention arm - nausea/vomiting occurred on the same day as starting ART and suspected peripheral 
neuropathy occurred after starting ART (patient did not start TB treatment). 
AE=adverse event. IQR=interquartile range. ART=antiretroviral therapy. TB=tuberculosis. 
 
 
 
 
